Use of Ozempic, a GLP-1 medication approved by the Food and Drug Administration (FDA) to treat diabetes, is increasing 75% (or $6.7 billion in spending) on a rolling 12-month average.1 This type of snowballing drug spend, if left unchecked, can cause plan premiums to soar, potentially pricing out members, leaving people who need drug coverage without the ability to pay for it
Q2: What are the primary research applications of AOD9604
At the same time, the two poles dont really resemble each other, which is puzzling, according to Bolton
If you or a loved one suffered an injury in a motorcycle accident in St
Evaluation of a melanocortin-4 receptor (Mc4r) agonist (Setmelanotide) in mc4r deficiency
The good news is that even a doubling of GLP-1 usage over the next five years would impact restaurant industry sales growth by less than 1% and traffic by about 5%, the report concludes